Can a Double-Dose vaccine strategy shield vulnerable vasculitis patients?
NCT ID NCT03069703
First seen Nov 20, 2025 · Last updated Jun 22, 2026 · Updated 28 times
Summary
This study tested whether giving a stronger pneumococcal vaccine schedule (either two doses close together or a single larger dose) followed by a standard booster could improve immune protection in 96 adults with ANCA-associated vasculitis who are also receiving rituximab therapy. The goal was to see if these 'reinforced' strategies are more effective and safe than the usual one-dose approach. The trial has completed, and results will show if the stronger schedules lead to better antibody responses against 12 pneumococcal serotypes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE PNEUMOCOCCAL INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pôle de Médecine Interne, Centre de référence " Maladies systémiques et autoimmunes rares, en particulier Vascularites nécrosantes et Sclérodermies systémiques " Hôpital Cochin, Assistance Publique-Hôpitaux de Paris
Paris, Paris, 75014, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pneumococcal vaccines (PCV13 and PPV23) and rituximab
What this could lead to
If successful, this could lead to better protection against pneumococcal infections for people with ANCA vasculitis who are on rituximab therapy.
What could go wrong
This is a small Phase 2 trial with only 96 participants, so results may not apply to everyone. The vaccines may not produce a strong immune response in these patients, and there is a risk of side effects like injection site reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.